[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

PURPOSE: One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [(89)Zr]Zr-cetuximab PET/CT as a potential predictive biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076055/
https://www.ncbi.nlm.nih.gov/pubmed/31705176
http://dx.doi.org/10.1007/s00259-019-04555-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076055/
https://www.ncbi.nlm.nih.gov/pubmed/31705176
http://dx.doi.org/10.1007/s00259-019-04555-6

Ejemplares similares